3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
10
Genitourinary
6
Thoracic
5
Gastrointestinal
5
Tumor-Agnostic
3
Head & Neck
3
Breast
3
Other hematologic neoplasm
2
Lymphoid
2
Gynecologic
2
CNS
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Conditions
Mesothelioma, Malignant
5
Unspecified Adult Solid Tumor, Protocol Specific
3
Solid Tumor, Adult
3
Solid Tumor
2
Pleural Effusion, Malignant
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Advanced Solid Tumors
1
Advanced Refractory Solid Tumors
1
Advanced Malignant Solid Tumor
1
Interventions
pembrolizumab
4
Cisplatin
3
Carboplatin
3
budigalimab
2
Pemetrexed
2
Paclitaxel
2
Immunotherapy
2
Etoposide
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
venetoclax
1
trametinib
1
spartalizumab
1
sargramostim
1
rovalpituzumab tesirine
1
ribociclib
1
poly ICLC
1
fludarabine
1
enzalutamide
1
entinostat
1
belinostat
1
UV1 vaccine
1
Tomography, Optical Coherence
1
Thrombopoietin
1
Sunitinib
1
Sirolimus
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Interleukin-2
×
Other solid neoplasm
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled